AR086094A1 - Derivados nucleosidicos 2’-azido sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades virales por vhc - Google Patents

Derivados nucleosidicos 2’-azido sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades virales por vhc

Info

Publication number
AR086094A1
AR086094A1 ARP120101281A ARP120101281A AR086094A1 AR 086094 A1 AR086094 A1 AR 086094A1 AR P120101281 A ARP120101281 A AR P120101281A AR P120101281 A ARP120101281 A AR P120101281A AR 086094 A1 AR086094 A1 AR 086094A1
Authority
AR
Argentina
Prior art keywords
group
alkylene
alkyl
haloalkyl
aryl
Prior art date
Application number
ARP120101281A
Other languages
English (en)
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of AR086094A1 publication Critical patent/AR086094A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/11—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Un compuesto que tiene la estructura de fórmula (1) o una sal farmacéuticamente aceptable del mismo, en la que: X es O, S o CH2; B es una base de purina o pirimidina natural o no natural, o B se selecciona entre uno de los restos del grupo de fórmulas (2); Y es N o -C(R19)-; Z es N o CH; R1 es H, o un resto del grupo de fórmulas (3); R2 es H o el resto de fórmula (4); o R1 y R2 se unen para formar un resto del grupo de fórmulas (5); R3 es alquilo C1-6, haloalquilo C1-6, hidroxialquilo C1-6, alquenilo C2-6, alquinilo C2-6 o cicloalquilo C3-7; cada uno de R4, R5, R7 y R8 es independientemente H, alquilo C1-6, haloalquilo C1-6, hidroxialquilo C1-6, halo, -OR20, -SR20 o -N(R20)2; cada uno de R6, R9, R10, R11 se selecciona independientemente entre H, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, heteroarilo monocíclico de 5 ó 6 miembros, heteroarilo bicíclico de 9 ó 10 miembros, heterocicloalquilo de 4 a 7 miembros, halo, -OR20, -SR20, -S(O)R20, -S(O)2R20, -S(O)2N(R20)2, -NHC(O)OR20, -NHC(O)N(R20)2, haloalquilo C1-6, hidroxialquilo C1-6, -O-(haloalquilo C1-6), -CN, -NO2, -N(R20)2, -NH(alquileno C1-6)-(heteroarilo monocíclico de 5 ó 6 miembros), -NH(alquileno C1-6)-(heteroarilo bicíclico de 9 ó 10 miembros), -C(O)R20, -C(O)OR20, -C(O)N(R20)2 y -NHC(O)R20, en la que dicho grupo alquenilo C2-6 y dicho grupo alquinilo C2-6 pueden estar opcionalmente sustituidos con un grupo halo; cada aparición de R12 se selecciona independientemente entre H, -(alquileno C1-6)-T-R21, -(alquileno C1-6)m-(arilo C6-10), -(alquileno C1-6)m-(heterocicloalquilo de 4 a 7 miembros), -(alquileno C1-6)m-(heterocicloalquenilo de 4 a 7 miembros), -CH(arilo C6-10)-C(O)OR20 y el resto de fórmula (6), donde dicho resto arilo C6-10 de dicho grupo -(alquileno C1-6)m-(arilo C6-10), dicho resto heterocicloalquilo de 4 a 7 miembros de dicho grupo -(alquileno C1-6)m-(heterocicloalquilo de 4 a 7 miembros) y dicho resto heterocicloalquenilo de 4 a 7 miembros de dicho grupo -(alquileno C1-6)m-(heterocicloalquenilo de 4 a 7 miembros) puede ser opcionalmente sustituido con hasta tres grupos, cada uno seleccionado independientemente entre alquilo C1-6, halo, -OR20, haloalquilo C1-6, -N(R20)2, -C(O)OR20, -C(O)N(R20)2 y -NHC(O)R20; R13 es H, -(alquileno C1-6)-T-R21 o -(alquileno C1-6)m-(arilo C6-10), o R12 y R13 pueden unirse para formar un grupo alquileno C2-4 entre los átomos de oxígeno a los cuales R12 y R13 están unidos, donde dicho grupo alquileno C2-4 está sustituido con por lo menos un grupo arilo C6-10, donde dicho resto arilo C6-10 de dicho grupo -(alquileno C1-6)m-(arilo C6-10) puede ser opcionalmente sustituido con hasta tres grupos, cada uno seleccionado independientemente del grupo puede ser opcionalmente sustituido con hasta tres grupos, cada uno seleccionado independientemente entre alquilo C1-6, halo, -OR20, haloalquilo C1-6, -N(R20)2, -C(O)OR20, -C(O)N(R20)2 y -NHC(O)R20; R14 es H, arilo C6-10, heteroarilo monocíclico de 5 ó 6 miembros o heteroarilo bicíclico de 9 ó 10 miembros, en la que dicho grupo arilo C6-10, dicho grupo heteroarilo monocíclico de 5 ó 6 miembros y dicho grupo heteroarilo bicíclico de 9 ó 10 miembros pueden estar opcionalmente sustituidos con R22; R15 es H, alquilo C1-6, cicloalquilo C3-7, fenilo o bencilo, en la que dicho alquilo C1-6 puede estar opcionalmente sustituido con un grupo seleccionado entre halo, -OR20, -SR20, guanidino, -N(R20)2, -C(O)OR20, -C(O)N(R20)2, -NHC(O)R20, heteroarilo monocíclico de 5 ó 6 miembros y heteroarilo bicíclico de 9 ó 10 miembros, y en la que dicho grupo fenilo y dicho grupo bencilo pueden estar opcionalmente sustituidos con hasta 2 grupos, cada uno seleccionado independientemente entre alquilo C1-6, halo y -OR20; R16 es H, alquilo C1-6, cicloalquilo C3-7, fenilo o bencilo, en la que dicho alquilo C1-6 puede estar opcionalmente sustituido con un grupo seleccionado entre halo, -OR20, -SR20, guanidino, -N(R20)2, -C(O)OR20, -C(O)N(R20)2, -NHC(O)R20, heteroarilo monocíclico de 5 ó 6 miembros y heteroarilo bicíclico de 9 ó 10 miembros, y en la que dicho grupo fenilo y dicho grupo bencilo pueden estar opcionalmente sustituidos con hasta 2 grupos, cada uno seleccionado independientemente entre alquilo C1-6, halo y -OR20; R17 es H, alquilo C1-20, alquenilo C2-20, -(alquileno C1-3)m-cicloalquilo C3-7, -(alquileno C1-3)m-arilo C6-10 o adamantilo, en la que dicho grupo alquilo C1-20, dicho grupo alquenilo C2-20, dicho grupo arilo C6-10 y dicho grupo adamantilo pueden estar opcionalmente sustituidos con hasta tres grupos, cada uno seleccionado independientemente entre halo, -OR20, -C(O)OR20, CN, NO2, haloalquilo C1-6, hidroxialquilo C1-6, cicloalquilo C3-7, arilo C6-10, heteroarilo monocíclico de 5 ó 6 miembros, heteroarilo bicíclico de 9 ó 10 miembros, -N(R20)2, -C(O)N(R20)2, -SR20, -S(O)R20, -S(O)2R20, -S(O)2N(R20)2, -NHC(O)R20, -NHC(O)OR20 y -NHC(O)N(R20)2 y; R18 es H, alquilo C1-6, cicloalquilo C3-7, -(alquileno C1-3)m-arilo C6-10, (alquileno C1-3)-C(O)OR20, heteroarilo monocíclico de 5 ó 6 miembros, heteroarilo bicíclico de 9 ó 10 miembros, heterocicloalquilo de 4 a 7 miembros o el resto de fórmula (6), en la que dicho grupo arilo C6-10, dicho grupo heteroarilo monocíclico de 5 ó 6 miembros y dicho grupo heteroarilo bicíclico de 9 ó 10 miembros pueden estar opcionalmente sustituidos con hasta cinco grupos, cada uno seleccionado independientemente entre alquilo C1-6, alquenilo C2-6, alquinilo C2-6, halo, -OR20, -SR20, haloalquilo C1-6, hidroxialquilo C1-6, -O-(haloalquilo C1-6), -CN, -NO2, -N(R20)2, -C(O)OR20, -C(O)N(R20)2 y -NHC(O)R20; R19 es H, alquilo C1-6, haloalquilo C1-6, hidroxialquilo C1-6, halo, -OR20, -SR20, N(R20)2, cicloalquilo C3-7, arilo C6-10, heteroarilo monocíclico de 5 ó 6 miembros o heteroarilo bicíclico de 9 ó 10 miembros; cada aparición de R20 es independientemente H, alquilo C1-6, haloalquilo C1-6, hidroxialquilo C1-6, -(alquileno C1-3)m-(cicloalquilo C3-7), -(alquileno C1-3)m-(arilo C6-10), -(alquileno C1-3)m-(heterocicloalquilo de 4 a 7 miembros), -(alquileno C1-3)m-(heteroarilo monocíclico de 5 ó 6 miembros) o -(alquileno C1-3)m-(heteroarilo bicíclico de 9 ó 10 miembros), en la que dicho grupo cicloalquilo C3-7, dicho grupo arilo C6-10, dicho grupo heterocicloalquilo de 4 a 7 miembros, dicho -(grupo heteroarilo monocíclico de 5 ó 6 miembros) o dicho grupo heteroarilo bicíclico de 9 ó 10 miembros puede estar opcionalmente sustituido con R26; cada aparición de R21 es independientemente H, alquilo C1-6, haloalquilo C1-6, hidroxialquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, cicloalquenilo C3-7, heteroarilo monocíclico de 5 ó 6 miembros, heteroarilo bicíclico de 9 ó 10 miembros, -OR20, -O-(haloalquilo C1-6) o -N(R20)2, en la que dicho grupo alquenilo C2-6, dicho grupo alquinilo C2-6, dicho grupo cicloalquilo C3-7, dicho grupo cicloalquenilo C3-7, dicho grupo arilo C6-10, dicho grupo heteroarilo monocíclico de 5 ó 6 miembros y dicho grupo heteroarilo bicíclico de 9 ó 10 miembros pueden estar opcionalmente sustituidos con hasta cinco grupos, cada uno seleccionado independientemente entre alquilo C1-6, alquenilo C2-6, alquinilo C2-6, halo, -OR20, -SR20, haloalquilo C1-6, hidroxialquilo C1-6, -O-(haloalquilo C1-6), -CN, -NO2, -N(R20)2, -C(O)R20, -C(O)OR20, -C(O)N(R20)2 y -NHC(O)R20; R22 representa de uno a cinco grupos de sustituyentes, cada uno seleccionado independientemente entre alquilo C1-6, halo, -OR20, -SR20, haloalquilo C1-6, hidroxialquilo C1-6, -O-(haloalquilo C1-6), -CN, -NO2, -N(R20)2, -C(O)OR20, -C(O)N(R20)2 y -NHC(O)R20, o dos grupos R22 cualesquiera en los átomos de carbono adyacentes del anillo pueden combinarse para formar -O-R23-O-; R23 es -[C(R24)2]n-; cada aparición de R24 es independientemente H o alquilo C1-6; cada aparición de R25 es independientemente seleccionado entre H, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, -(alquileno C1-3)m-(arilo C6-10), -(alquileno C1-6)m-(alquilo C1-6), -(alquileno C1-6)-C(O)O-(alquilo C1-6), heterocicloalquilo de 4 a 7 miembros, heteroarilo monocíclico de 5 ó 6 miembros y heteroarilo bicíclico de 9 ó 10 miembros, en la que dicho grupo alquilo C1-6, dicho grupo alquenilo C2-6, dicho grupo alquinilo C2-6, dicho grupo cicloalquilo C3-7, dicho grupo arilo C6-10, dicho grupo heterocicloalquilo de 4 a 7 miembros, dicho -(grupo heteroarilo monocíclico de 5 ó 6 miembros) o dicho grupo heteroarilo bicíclico de 9 ó 10 miembros puede estar opcionalmente sustituido con R26; o dos grupos R25, junto con el átomo de nitrógeno común al que están unidos, se unen para formar un grupo heterocicloalquilo de 4 a 7 miembros; R26 representa de uno a cinco grupos de sustituyentes, cada uno seleccionado independientemente entre alquilo C1-6, alquenilo C2-6, alquinilo C2-6, halo, -OR27, -SR27, haloalquilo C1-6, hidroxialquilo C1-6, -O-(haloalquilo C1-6), -CN, -NO2, -N(R27)2, -C(O)OR27, -C(O)N(R27)2 y -NHC(O)R27; cada aparición de R27 es independientemente H, alquilo C1-6, haloalquilo C1-6, hidroxialquilo C1-6, -(alquileno C1-3)m-(cicloalquilo C3-7), -(alquileno C1-3)m-(arilo C6-10), -(alquileno C1-3)m-(heterocicloalquilo de 4 a 7 miembros), -(alquileno C1-3)m-(heteroarilo monocíclico de 5 ó 6 miembros) o -(alquileno C1-3)m-(heteroarilo bicíclico de 9 ó 10 miembros); R28 es H, alquilo C1-6, haloalquilo C1-6, hidroxialquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, cicloalquenilo C3-7, heteroarilo monocíclico de 5 ó 6 miembros, heteroarilo bicíclico de 9 ó 10 miembros, -OR20, -O-(haloalquilo C1-6) o -N(R20)2, en la que dicho grupo alquenilo C2-6, dicho grupo alquinilo C2-6, dicho grupo cicloalquilo C3-7, dicho grupo cicloalquenilo C3-7, dicho grupo arilo C6-10, dicho grupo heteroarilo monocíclico de 5 ó 6 miembros y dicho grupo heteroarilo bicíclico de 9 ó 10 miembros pueden estar opcionalmente sustituidos con hasta cinco grupos, cada uno seleccionado independientemente entre alquilo C1-6, alquenilo C2-6, alquinilo C2-6, halo, -OR20, -SR20, haloalquilo C1-6, hidroxial
ARP120101281A 2011-04-13 2012-04-13 Derivados nucleosidicos 2’-azido sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades virales por vhc AR086094A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161475076P 2011-04-13 2011-04-13

Publications (1)

Publication Number Publication Date
AR086094A1 true AR086094A1 (es) 2013-11-20

Family

ID=47009661

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120101281A AR086094A1 (es) 2011-04-13 2012-04-13 Derivados nucleosidicos 2’-azido sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades virales por vhc

Country Status (5)

Country Link
US (1) US9156872B2 (es)
EP (1) EP2697242B1 (es)
AR (1) AR086094A1 (es)
TW (1) TW201311715A (es)
WO (1) WO2012142075A1 (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EA200601591A1 (ru) * 2000-05-26 2007-02-27 Айденикс (Кайман) Лимитед Применение рибонуклеозидных соединений для лечения флавивирусных и пестивирусных инфекций
EP1576138B1 (en) 2002-11-15 2017-02-01 Idenix Pharmaceuticals LLC. 2'-methyl nucleosides in combination with interferon and flaviviridae mutation
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
EP2691409B1 (en) 2011-03-31 2018-02-21 Idenix Pharmaceuticals LLC. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
EP2755983B1 (en) 2011-09-12 2017-03-15 Idenix Pharmaceuticals LLC. Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
EP2755982A4 (en) * 2011-09-14 2015-03-25 Merck Sharp & Dohme SILICULAR HETEROCYCLIC DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES
US8507460B2 (en) 2011-10-14 2013-08-13 Idenix Pharmaceuticals, Inc. Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
EP2852604B1 (en) * 2012-05-22 2017-04-12 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphoramidate prodrugs for hcv infection
AU2013266393B2 (en) * 2012-05-22 2017-09-28 Idenix Pharmaceuticals Llc D-amino acid compounds for liver disease
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
EA027929B1 (ru) 2012-05-25 2017-09-29 Янссен Сайенсиз Айрлэнд Юси Нуклеозиды на основе урацила и спирооксетана
WO2014052638A1 (en) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
ES2674980T3 (es) 2012-10-08 2018-07-05 Idenix Pharmaceuticals Llc Análogos de 2'-cloro nucleósidos para infección por VHC
AR092959A1 (es) * 2012-10-17 2015-05-06 Merck Sharp & Dohme Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
WO2014059902A1 (en) * 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. 2'-disubstituted substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases
WO2014059901A1 (en) * 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. 2'-cyano substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases
US10723754B2 (en) 2012-10-22 2020-07-28 Idenix Pharmaceuticals Llc 2′,4′-bridged nucleosides for HCV infection
US9732111B2 (en) * 2012-11-19 2017-08-15 Merck Sharp & Dohme Corp. 2′-alkynyl substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EP2935304A1 (en) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
US9309275B2 (en) 2013-03-04 2016-04-12 Idenix Pharmaceuticals Llc 3′-deoxy nucleosides for the treatment of HCV
EP2970357A1 (en) * 2013-03-13 2016-01-20 IDENIX Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
RU2534613C2 (ru) * 2013-03-22 2014-11-27 Александр Васильевич Иващенко Алкил 2-{ [(2r,3s,5r)-5-(4-амино-2-оксо-2н-пиримидин-1-ил)- -гидрокси-тетрагидро-фуран-2-илметокси]-фенокси-фосфориламино} -пропионаты, нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения
WO2014165542A1 (en) 2013-04-01 2014-10-09 Idenix Pharmaceuticals, Inc. 2',4'-fluoro nucleosides for the treatment of hcv
BR112015025716A2 (pt) 2013-04-12 2017-07-18 Achillion Pharmaceuticals Inc pró-fármacos de nucleosídeo submetidos a deutério úteis para o tratamento de hcv
CN104151360B (zh) * 2013-05-14 2019-02-22 北京美倍他药物研究有限公司 磷酸/膦酸衍生物及其医药用途
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
EP3027636B1 (en) 2013-08-01 2022-01-05 Idenix Pharmaceuticals LLC D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
US8889701B1 (en) * 2013-10-11 2014-11-18 Alla Chem, Llc Substituted (S)-(2R,3R,5R)-3-hydroxy-(5-pyrimidin-1-yl)tetrahydrofuran-2-ylmethyl aryl phosphoramidate
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
CN104804042B (zh) * 2014-01-24 2018-01-19 齐鲁制药有限公司 核苷酸膦酸酯类化合物、其药物组合物、制备方法及用途
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
CN104119385B (zh) * 2014-07-24 2017-04-05 廖国超 核苷类似物的磷酸酯前药及其应用
TWI678369B (zh) 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類
TWI673283B (zh) 2014-08-21 2019-10-01 美商基利科學股份有限公司 ２’－氯胺基嘧啶酮及嘧啶二酮核苷類
UA124966C2 (uk) 2015-03-06 2021-12-22 Атеа Фармасеутікалс, Інк. <font face="Symbol">b</font>-D-2'-ДЕЗОКСИ-2'-<font face="Symbol">a</font>-ФТОР-2'-<font face="Symbol">b</font>-C-ЗАМІЩЕНІ-2-МОДИФІКОВАНІ-N<sup>6</sup>-ЗАМІЩЕНІ ПУРИНОВІ НУКЛЕОТИДИ ДЛЯ ЛІКУВАННЯ ВИКЛИКАНИХ HCV ЗАХВОРЮВАНЬ
GEP20207182B (en) 2015-08-13 2020-11-25 Merck Sharp & Dohme Cyclic di-nucleotide compounds as sting agonists
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
CN107849075A (zh) * 2016-01-19 2018-03-27 四川海思科制药有限公司 一种核苷类似物的磷酰胺酯前药及其应用
KR20180122333A (ko) * 2016-03-25 2018-11-12 장쑤 태슬리 디이 파마슈티컬 컴퍼니 리미티드 우리딘 포스포르아미드 프로드럭, 그의 제조 방법 및 그의 의약적 용도
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
GB201609601D0 (en) * 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
EP3865136A1 (en) * 2016-09-07 2021-08-18 ATEA Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for corona virus treatment
CN106432328B (zh) * 2016-09-14 2019-03-22 江苏福瑞生物医药有限公司 一种索非布韦中间体的制备方法
RS62410B1 (sr) 2016-10-04 2021-10-29 Merck Sharp & Dohme Benzo[b]tiofenska jedinjenja kao agonisti sting
KR20230151050A (ko) 2017-02-01 2023-10-31 아테아 파마슈티컬즈, 인크. C형 간염 바이러스를 치료하기 위한 뉴클레오티드 헤미-술페이트 염
US11466047B2 (en) 2017-05-12 2022-10-11 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
AU2018311965A1 (en) 2017-08-04 2020-02-13 Merck Sharp & Dohme Llc Combinations of PD-1 antagonists and benzo[b]thiophene sting antagonists for cancer treatment
MA49772A (fr) 2017-08-04 2021-04-21 Merck Sharp & Dohme Agonistes benzo[b]thiophène de sting pour le traitement du cancer
EP3727401A4 (en) 2017-12-20 2022-04-06 Merck Sharp & Dohme Corp. CYCLIC DINUCLEOTIDE COMPOUNDS USED AS STING AGONISTS
CA3095646A1 (en) 2018-04-03 2019-10-10 Merck Sharp & Dohme Corp. Benzothiophenes and related compounds as sting agonists
WO2019195063A1 (en) 2018-04-03 2019-10-10 Merck Sharp & Dohme Corp. Aza-benzothiophene compounds as sting agonists
TW202012001A (zh) 2018-04-10 2020-04-01 美商亞堤製藥公司 C型肝炎病毒(hcv)感染硬化之患者的治療
CN113214262B (zh) * 2020-02-05 2023-07-07 华创合成制药股份有限公司 一种含有胍基的化合物及其制备方法和用途
US20210292348A1 (en) 2020-02-18 2021-09-23 Gilead Sciences, Inc. Antiviral compounds
TWI791193B (zh) 2020-02-18 2023-02-01 美商基利科學股份有限公司 抗病毒化合物
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
CN111233869B (zh) * 2020-03-12 2022-09-16 杭州新博思生物医药有限公司 用于制备瑞德西韦关键中间体的新化合物及其制备方法
WO2022221514A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
CN113234102A (zh) * 2021-05-18 2021-08-10 宁波大学 一种三配位磷衍生物及中间体及制备方法
WO2023201072A1 (en) * 2022-04-15 2023-10-19 Crestone, Inc. Novel 6-azauridine compounds as broad spectrum antiviral agents

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1187824A (en) 1913-05-16 1916-06-20 Harold O Ersin Bed-bottom.
US3480613A (en) 1967-07-03 1969-11-25 Merck & Co Inc 2-c or 3-c-alkylribofuranosyl - 1-substituted compounds and the nucleosides thereof
US4211773A (en) 1978-10-02 1980-07-08 Sloan Kettering Institute For Cancer Research 5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
AU575854B2 (en) 1983-10-04 1988-08-11 Shionogi & Co., Ltd. 7beta-(carboxyalkenamido) cephalosporins
US4666892A (en) 1984-03-06 1987-05-19 Sloan-Kettering Memorial Cancer Center Method and composition for hepatitis treatment with pyrimidine nucleoside compounds
NZ220764A (en) 1986-07-02 1989-09-27 Shionogi & Co Crystalline form of 7beta((z)-2-(2-aminothiazol-4-yl)-4- carboxybut-2-enoylamino)-3-cephem-4-carboxylic acid and pharmaceutical compositions
US5017380A (en) 1986-07-02 1991-05-21 Shionogi & Co., Ltd. Gelatin hard capsule containing crystalline hydrate of oral cephalosporin
ES2012739T5 (es) 1987-11-18 2001-12-01 Chiron Corp Diagnosticos para nanbv.
DE69024378T2 (de) 1989-02-01 1996-09-12 Asahi Glass Co Ltd Azeotrope oder azeotropähnliche Zusammensetzung auf der Basis von Chlorfluorkohlenwasserstoffen
US6110901A (en) 1990-07-03 2000-08-29 American Cyanamid Company Method for treating RNA viral infections by using RNA chain terminators
WO1993018051A1 (en) 1992-03-11 1993-09-16 Japan Tobacco Inc. Process for producing nucleoside derivative
GB9218810D0 (en) 1992-09-04 1992-10-21 Univ Birmingham Antiviral pyrimidine nucleosides
US5837852A (en) 1993-10-14 1998-11-17 Bristol-Myers Squibb Company Capped nucleic acid oligomers that inhibit cap-dependent transcription of the influenza virus endonuclease
US5672594A (en) 1994-10-24 1997-09-30 Genencor International, Inc. L-erythrosyl nucleosides
US5977061A (en) 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
US5916791A (en) 1995-11-24 1999-06-29 Hirschberg; Joseph Polynucleotide molecule from Haematococcus pluvialis encoding a polypeptide having a β--C--4--oxygenase activity for biotechnological production of (3S,3S)astaxanthin
US5922757A (en) 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
CZ126799A3 (cs) 1996-10-16 1999-07-14 Icn Pharmaceuticals Purinové L-nukleosidy a jejich analogy a farmaceutické prostředky, které je obsahují
JP4080541B2 (ja) 1996-10-18 2008-04-23 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ、特にｃ型肝炎ウイルスｎｓ３プロテアーゼの阻害因子
US6063628A (en) 1996-10-28 2000-05-16 University Of Washington Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
EP1012180B1 (en) 1997-08-11 2004-12-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptide analogues
US6767991B1 (en) 1997-08-11 2004-07-27 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptides
ATE344271T1 (de) 1998-02-25 2006-11-15 Univ Emory 2'-fluoronukleoside
US6831069B2 (en) 1999-08-27 2004-12-14 Ribapharm Inc. Pyrrolo[2,3-d]pyrimidine nucleoside analogs
EP1225899A2 (en) 1999-11-04 2002-07-31 Virochem Pharma Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
TR200103147T1 (tr) 1999-12-27 2002-06-21 Japan Tobacco Inc. Kaynaşık halkalı bileşikler ve bunların ilaç olarak kullanımı.
CN1427722A (zh) 2000-02-18 2003-07-02 希拉生物化学股份有限公司 用核苷类似物治疗或预防黄病毒感染的方法
AU2001251165A1 (en) 2000-04-03 2001-10-15 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
AR029903A1 (es) 2000-04-05 2003-07-23 Schering Corp Inhibidores macrociclicos de la ns3-serina proteasa, del virus de la hepatitis c, que comprenden partes p2 n-ciclicas, composiciones farmaceuticas y utilizacion de los mismos para la manufactura de un medicamento
ES2319732T3 (es) 2000-04-13 2009-05-12 Pharmasset, Inc. Derivados de nucleosido 3'- o 2'-hidroximetilo sustituido para el tratamiento de infecciones virales.
CN1432022A (zh) 2000-04-19 2003-07-23 先灵公司 含有烷基和芳基丙氨酸p2部分的丙型肝炎病毒的大环ns3－丝氨酸蛋白酶抑制剂
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EA200601591A1 (ru) 2000-05-26 2007-02-27 Айденикс (Кайман) Лимитед Применение рибонуклеозидных соединений для лечения флавивирусных и пестивирусных инфекций
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
US7012066B2 (en) 2000-07-21 2006-03-14 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
WO2002008251A2 (en) 2000-07-21 2002-01-31 Corvas International, Inc. Peptides as ns3-serine protease inhibitors of hepatitis c virus
CZ2003195A3 (cs) 2000-07-21 2003-04-16 Schering Corporation Peptidové inhibitory serinové proteázy NS3 a farmaceutický prostředek
AR034127A1 (es) 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
BR0114837A (pt) 2000-10-18 2006-05-09 Pharmasset Ltd nucleosìdeos modificados para tratamento de infecções viróticas e proliferação celular anormal
MXPA03005219A (es) 2000-12-12 2003-09-25 Schering Corp Peptidos diarilicos como inhibidores de ns3-serina proteasa en hepatitis de virus c.
KR20030081343A (ko) 2000-12-15 2003-10-17 파마셋, 리미티드 플라비비리다에 감염 치료용 항바이러스제
WO2002057287A2 (en) 2001-01-22 2002-07-25 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US7105499B2 (en) 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
AU2002252183A1 (en) 2001-03-06 2002-09-19 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
GB0112617D0 (en) 2001-05-23 2001-07-18 Hoffmann La Roche Antiviral nucleoside derivatives
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
EP1404694A1 (en) 2001-06-21 2004-04-07 Glaxo Group Limited Nucleoside compounds in hcv
US6949522B2 (en) 2001-06-22 2005-09-27 Pharmasset, Inc. β-2′- or 3′-halonucleosides
US6887690B2 (en) 2001-06-22 2005-05-03 Pe Corporation Dye-labeled ribonucleotide triphosphates
US6585967B2 (en) 2001-07-05 2003-07-01 Closure Medical Corporation Adhesive treatment for tinea cruris
ATE349463T1 (de) 2001-07-11 2007-01-15 Vertex Pharma Verbrückte bizyklische serinproteaseinhibitoren
WO2003015798A1 (en) 2001-08-14 2003-02-27 Toyama Chemical Co., Ltd. Novel virus proliferation inhibition/virucidal method and novel pyradine nucleotide/pyradine nucleoside analogue
WO2003026675A1 (en) 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
JP2005504087A (ja) 2001-09-28 2005-02-10 イデニクス（ケイマン）リミテツド ４’が修飾されたヌクレオシドを使用するｃ型肝炎ウイルス治療のための方法および組成物
WO2003051898A1 (en) 2001-12-17 2003-06-26 Ribapharm Inc. Unusual nucleoside libraries, compounds, and preferred uses as antiviral and anticancer agents
WO2003051897A1 (en) 2001-12-17 2003-06-26 Ribapharm Inc. Nucleoside analog libraries and compounds
AU2002353165A1 (en) 2001-12-17 2003-06-30 Ribapharm Inc. Deazapurine nucleoside libraries and compounds
AU2002340387A1 (en) 2001-12-17 2003-06-30 Ribapharm Inc. Cytidine libraries and compounds synthesized by solid-phase combinatorial strategies
WO2003051881A1 (en) 2001-12-17 2003-06-26 Ribapharm Inc. Substituted purine nucleoside libraries and compounds by solid-phase combinatorial strategies
EP1572705A2 (en) 2002-01-17 2005-09-14 Ribapharm, Inc. Sugar modified nucleosides as viral replication inhibitors
PE20030857A1 (es) 2002-01-23 2003-10-25 Schering Corp Compuestos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c
CA2477741A1 (en) 2002-02-28 2003-09-04 Biota, Inc. Nucleotide mimics and their prodrugs
NZ561851A (en) 2002-04-11 2009-05-31 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus NS3 - NS4 protease
CA2484921A1 (en) 2002-05-06 2003-11-13 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis c virus infection
PL374792A1 (en) 2002-06-28 2005-10-31 Idenix (Cayman) Limited 2' and 3'-nucleoside prodrugs for treating flaviviridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
CA2506415A1 (en) 2002-11-19 2004-06-03 Achillion Pharmaceuticals, Inc. Substituted aryl thioureas and releated compounds; inhibitors of viral replication
WO2004080989A1 (ja) 2003-03-10 2004-09-23 Sumitomo Chemical Company Limited フラン化合物の製造方法
TW200510391A (en) 2003-04-11 2005-03-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
CA2521678A1 (en) 2003-04-11 2004-10-28 Vertex Pharmaceuticals, Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
ES2726998T3 (es) 2003-05-30 2019-10-11 Gilead Pharmasset Llc Análogos de nucleósidos fluorados modificados
WO2005003047A1 (en) 2003-07-03 2005-01-13 Philips Intellectual Property & Standards Gmbh Pane which can be heated by means of invisible light
CA2536570A1 (en) 2003-08-26 2005-03-10 Schering Corporation Novel peptidomimetic ns3-serine protease inhibitors of hepatitis c virus
KR20060085248A (ko) 2003-09-26 2006-07-26 쉐링 코포레이션 Ｃ형 간염 바이러스 ｎｓ3 세린 프로테아제의마크로사이클릭 억제제
AR046833A1 (es) 2003-11-10 2005-12-28 Schering Corp Anticuerpos anti-interleuquina-10
EP1689770A1 (en) 2003-11-20 2006-08-16 Schering Corporation Depeptidized inhibitors of hepatitis c virus ns3 protease
AU2004298498B2 (en) 2003-12-11 2008-09-11 Schering Corporation Inhibitors of hepatitis C virus NS3/NS4a serine protease
RU2006134002A (ru) 2004-02-27 2008-04-10 Шеринг Корпорейшн (US) Новые соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с
ATE438622T1 (de) 2004-02-27 2009-08-15 Schering Corp 3,4-(cyclopentyl)kondensierte prolinverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
TW200536528A (en) 2004-02-27 2005-11-16 Schering Corp Novel inhibitors of hepatitis C virus NS3 protease
WO2005085242A1 (en) 2004-02-27 2005-09-15 Schering Corporation Novel ketoamides with cyclic p4's as inhibitors of ns3 serine protease of hepatitis c virus
US7635694B2 (en) 2004-02-27 2009-12-22 Schering Corporation Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease
WO2005087721A2 (en) 2004-02-27 2005-09-22 Schering Corporation Compounds as inhibitors of hepatitis c virus ns3 serine protease
TWI314927B (en) 2004-02-27 2009-09-21 Schering Corporatio Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease
US7816326B2 (en) 2004-02-27 2010-10-19 Schering Corporation Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
US20050249702A1 (en) 2004-05-06 2005-11-10 Schering Corporation (1R,2S,5S)-N-[(1S)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide as inhibitor of hepatitis C virus NS3/NS4a serine protease
US20070265222A1 (en) 2004-06-24 2007-11-15 Maccoss Malcolm Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection
US8013006B2 (en) 2004-07-14 2011-09-06 Ptc Therapeutics, Inc. Methods for treating hepatitis C
MX2007000762A (es) 2004-07-22 2007-04-02 Ptc Therapeutics Inc Tienopiridinas para tratamientode hepatitis c.
AU2006235438A1 (en) 2005-04-11 2006-10-19 Achillion Pharmaceuticals, Inc. Pharmaceutical compositions for and methods of inhibiting HCV replication
US7405204B2 (en) 2005-04-25 2008-07-29 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
CA2618335C (en) 2005-08-15 2015-03-31 F.Hoffmann-La Roche Ag Antiviral phosphoramidates of 4'-substituted pronucleotides
MX2008010355A (es) 2006-02-09 2008-10-31 Schering Corp Combinaciones que comprenden inhibidores de proteasa del virus de la hepatitis c e inhibidores de polimerasa del virus de la hepatitis c, y metodos de tratamiento relacionados con los mismos.
AU2007215114A1 (en) 2006-02-14 2007-08-23 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
ATE543808T1 (de) 2006-12-22 2012-02-15 Schering Corp 5,6-ring-annelierte indolderivate und ihre verwendung
KR20090106539A (ko) 2006-12-22 2009-10-09 쉐링 코포레이션 Ｈｃｖ 및 관련 바이러스 감염을 치료 또는 예방하기 위한 4,5-환 환상 인돌 유도체
US8557848B2 (en) 2006-12-22 2013-10-15 Merck Sharp & Dohme Corp. 4,5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
WO2008083352A1 (en) 2006-12-29 2008-07-10 Genifuel Corporation Production of biofuels using algae
WO2008100447A2 (en) 2007-02-09 2008-08-21 Gilead Sciences, Inc. Nucleoside analogs for antiviral treatment
KR20100049667A (ko) 2007-08-29 2010-05-12 쉐링 코포레이션 바이러스 감염 치료용 2,3-치환된 인돌 유도체
KR20100061819A (ko) 2007-08-29 2010-06-09 쉐링 코포레이션 바이러스 감염 치료 또는 예방용 테트라사이클릭 인돌 유도체 및 이의 용도
BRPI0815811A2 (pt) 2007-08-29 2015-02-18 Schering Corp Derivados de indol substituído e métodos de uso dos mesmos
WO2009032125A1 (en) 2007-08-29 2009-03-12 Schering Corporation 2,3-substituted azaindole derivatives for treating viral infections
WO2009132135A1 (en) * 2008-04-23 2009-10-29 Gilead Sciences, Inc. 1' -substituted carba-nucleoside analogs for antiviral treatment
BRPI0922508A8 (pt) 2008-12-23 2016-01-19 Pharmasset Inc Análogos de nucleosídeo
CA2748057C (en) 2008-12-23 2018-07-03 Pharmasset, Inc. Nucleoside phosphoramidates
DE102009000180A1 (de) 2009-01-13 2010-07-15 Evonik Degussa Gmbh Verfahren zur Herstellung von mehrschichtig beschichteten Gummipartikeln und mehrschichtig beschichtete Gummipartikel
EA020898B1 (ru) 2009-03-27 2015-02-27 Мерк Шарп Энд Домэ Корп. Ингибиторы репликации вируса гепатита c
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
WO2010135520A1 (en) 2009-05-20 2010-11-25 Chimerix, Inc. Compounds, compositions and methods for treating viral infection
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
US7973013B2 (en) 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
WO2012125900A1 (en) 2011-03-16 2012-09-20 Enanta Pharmaceuticals, Inc. 2'-allene-substituted nucleoside derivatives
EP2696681B1 (en) * 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases

Also Published As

Publication number Publication date
EP2697242A1 (en) 2014-02-19
US9156872B2 (en) 2015-10-13
EP2697242B1 (en) 2018-10-03
TW201311715A (zh) 2013-03-16
US20140206640A1 (en) 2014-07-24
EP2697242A4 (en) 2014-10-01
WO2012142075A1 (en) 2012-10-18

Similar Documents

Publication Publication Date Title
AR086094A1 (es) Derivados nucleosidicos 2’-azido sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades virales por vhc
AR086096A1 (es) Derivados de nucleosidos 2’-ciano sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
AR086095A1 (es) Derivados de nucleosidos 2’-sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
AR066898A1 (es) Derivados de fosforamidato de nucleosidos. procesos de obtencion y composiciones farmaceuticas.
RU2015143990A (ru) Трициклические соединения в качестве ингибиторов иммуносупрессии, опосредуемой метаболизированием триптофана
AR092959A1 (es) Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
AR127309A2 (es) Derivados de piridazinona
AR086546A1 (es) Derivados de 7h-purin-8(9h)-ona como inhibidores de jak
AR063804A1 (es) Compuestos de azoniabiciclo[2.2.2]octano
AR081848A1 (es) Inhibidores de la proteina ns5a del vhc
AR053311A1 (es) Macrolonas - quinolonas amino sustituidas
RU2009102252A (ru) Хиноксалинилмакроциклические ингибиторы серинпротеазы вируса гепатита с
AR084976A1 (es) Compuestos de bifenileno sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
EA200900358A1 (ru) Энантиомерно чистые фосфоиндолы в качестве ингибиторов hiv
AR087792A1 (es) Compuestos heterociclicos tetraciclicos y metodos para el uso de los mismos en el tratamiento de enfermedades virales
AR082152A1 (es) Derivados de n-(metilsulfonil)benzamida, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de nav1.7
RU2010111550A (ru) 2,3-замещенные индольные производные для лечения вирусных инфекций
AR087184A1 (es) Derivados de azaindol utiles para tratar infecciones por hiv y composiciones farmaceuticas que los contienen
AR082994A1 (es) Derivados de pirazina como bloqueadores del canal epitelial de sodio
AR069412A1 (es) Derivados de pirimidina, proceso para prepararlos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades virales, bacterianas y alergicas, entre otras.
AR086144A1 (es) Derivados de pirrolotriazinona como inhibidores de pi3k
HRP20020926B1 (en) Arylmethylamine derivatives for use as tryptase inhibitors
AR059571A1 (es) Derivados de octahidro-pirrolo[3,4-c]pirrol, composiciones farmaceuticas
AR064414A1 (es) Derivados de 1-azoniabiciclo[2, 2, 2]octano y 1-azabiciclo[2, 2, 2]oct-3-ilo, un proceso para su preparacion, una composicion farmaceutica que los comprende, procedimiento de obtencion de la misma, su uso en la elaboracion de un medicamento para el tratamiento de epoc y un producto farmaceutico que
AR045407A1 (es) Compuesto de tiazolidin-4-ona, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion

Legal Events

Date Code Title Description
FA Abandonment or withdrawal